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ABSTRACT 
 
Oral squamous cell carcinoma (OSCC) is the most common cancer of the head and neck. 
It represents the most prominent malignant neoplasm for dental surgeons. It is usually detected 
in advanced clinical stages, and despite the medical advances, patients still have a poor clinical 
prognosis. It justifies the search for prognostic biomarkers that represent the staging of the 
disease, as well as understand molecular mechanisms that control its physiopathology. The 
objective of this doctoral thesis was to identify the prognostic biomarkers provided in 
biomedical literature, as well as to deepen the understanding of the role of a proteoglycan named 
agrin. Agrin proved to be relevant in several oncogenic events in previous studies published by 
our group. To achieve our first objective, we performed a systematic review of the literature. In 
this study, we used the MEDLINE/PubMed database and keywords associated with patient risk 
and common OSCC clinical endpoints: overall survival, disease-free survival and cause-
specific survival. This approach produced an article that identified 41 potential prognostic 
biomarkers, mainly proteins evaluated by immunohistochemistry. These potential biomarkers 
must be clinically evaluated in new clinical studies. For the second aim of this thesis, we 
silenced the expression of agrin (using shRNA technology) in different cell lines and identified 
the protein network associated with agrin through mass spectrometry-based proteomics. We 
assessed the prognostic value of this network using bioinformatics tools and public databases. 
Our results suggest that agrin is essential for the oncogenic events associated with the 
progression of the OSCC, both in vivo and in vitro, which led us to conclude that agrin is a 
strong candidate as a therapeutic target for OSCC. 
 
Key Words: Mouth neoplasms. Carcinoma, squamous cell. Tumor biomarkers. Agrin. 
Proteomics. 
  
RESUMO 
 
O carcinoma de células escamosas da cavidade oral (CECO) é o câncer mais comum na 
região da cabeça e pescoço. O CECO representa a neoplasia maligna mais importante para os 
cirurgiões dentistas. É detectado geralmente em estágios clínicos avançados e, apesar dos 
progressos da medicina, os pacientes ainda apresentam um prognóstico clínico desfavorável. 
Esse contexto justifica a busca de biomarcadores prognósticos que representem o estadiamento 
da doença, além de compreender os mecanismos moleculares que controlam sua fisiopatologia. 
Os objetivos desta tese de doutorado foram identificar os potenciais biomarcadores 
prognósticos para CECO descritos na literatura biomédica, bem como aprofundar a 
compreensão do papel do proteoglicano agrina. Essa proteína mostrou-se relevante em vários 
eventos oncogênicos em estudos prévios publicados por nosso grupo. Para alcançar nosso 
primeiro objetivo, realizamos uma revisão sistemática da literatura. Nesse estudo, utilizamos a 
base de dados MEDLINE/PubMed e palavras-chave associando o risco dos pacientes com os 
seguintes desfechos clínicos para CECO: sobrevida global, sobrevida livre de doença e 
sobrevida doença-específica. Essa abordagem resultou na publicação de um artigo que 
identificou 41 potenciais biomarcadores prognósticos em CECO, principalmente proteínas 
avaliadas por inmunohistoquímica. Esses potenciais biomarcadores devem ser avaliados em 
novos estudos clínicos. Para o segundo objetivo desta tese, silenciamos a expressão de agrina 
(utilizando a tecnologia shRNA) em diferentes linhagens celulares e identificamos a rede de 
proteínas associadas a agrina através de proteômica baseada em espectrometria de massas. O 
valor prognóstico desta rede foi avaliado utilizando ferramentas de bioinformática e bancos de 
dados públicos. Nossos resultados sugerem que a proteína agrina é essencial para os eventos 
oncogênicos associados à progressão do CECO, tanto in vivo como in vitro, o que nos leva a 
concluir que agrina é um forte candidato como alvo terapêutico para o CECO. 
 
Palavras-chave: Neoplasias bucais. Carcinoma de células escamosas. Biomarcadores tumorais. 
Agrina. Proteômica. 
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1 INTRODUCTION 
 
Oral cancer is a highly relevant problem of global public health, especially for dentistry. 
Despite the progress in research and therapy, survival has not improved significantly in the last 
years, representing a continuing challenge for biomedical sciences. 
Oral cancer is a malignant neoplasia which arises on the lip or oral cavity. It is 
traditionally defined as a squamous cell carcinoma (OSCC) (Rivera, 2015). OSCC represents 
95% of all forms of head and neck squamous cell carcinoma (HNSCC) (Rivera and Venegas, 
2014), constituting the most common malignancy of head and neck region (Chi et al., 2015). 
Oral cancer is two to three times more prevalent in men than women in most ethnic groups. In 
worldwide reports, cancers of all regions of the oral cavity and pharynx are grouped and 
collectively represent the sixth most common cancer in the world (Rivera, 2015). 
OSCC is a preventable disease, where smoking and alcohol-considered major risk 
factors-are present in 90% of cases (Dissanayaka et al., 2012), having both a synergic effect 
(Koontongkaew, 2013). Among other risk factors, there is the human papillomavirus (HPV, 
mainly associated with nonkeratinizing squamous cell carcinoma of the oropharynx) (Dalianis, 
2014) and ultraviolet radiation (associated with carcinoma of lips)(Gallagher et al., 2010). 
OSCC can be presented as a “natural history”, which originates from non-aberrant 
keratinocytes which are chronically exposed to a stimulus that breaks its homeostasis, following 
an epithelial hyperplasia, dysplasia in different degrees, carcinoma in situ and an invasive 
carcinoma leading to the generation of distant metastases, with the consequent clinical 
manifestations (Rivera, 2015). 
Despite the fact that cancer occurs in a part of the body that is readily accessible for 
early detection, most carcinomas are not diagnosed until they have reached advanced stages 
(Jafari et al., 2013). In addition, therapeutic alternatives (surgery, radiation and 
chemotherapy) remain highly expensive and disfiguring (CDC, 2013). These precedents justify 
the search and need for OSCC biomarkers. 
The term biomarker refers to a measurement variable that is associated with disease 
outcome (Ballman, 2015). They can be used for patient assessment in multiple clinical 
scenarios, including estimating the risk of disease and distinguishing benign from malignant 
lesions (Henry and Hayes, 2012). Tumor markers are mostly useful in evaluating the 
progression of the disease status (Kabel, 2017). They can be classified in predictive, diagnostic 
and prognostic biomarkers (Mishra and Verma, 2010).  
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Prognostic tumor markers aim to objectively evaluate the patient’s cancer outcome (e.g., 
overall survival, disease-free survival, and cause-specific survival) independent of treatment 
received (Ballman, 2015). The presence or absence of a prognostic marker can be useful for the 
selection of a better therapeutic regimen (Mehta et al., 2010). 
Today, it is accepted that HPV status is a HNSCC biomarker. HPV-associated HNSCCs 
(nonkeratinizing) form a distinct clinical entity with favorable outcomes (Dok and Nuyts, 2016; 
TCGA, 2015). The current National Comprehensive Cancer Network (NCCN) guidelines state 
that “HPV testing is valuable prognostically; however, the results should not change 
management decisions" (Adelstein et al., 2017). Therefore, it is necessary to identify other 
biomarkers that can assist in these decisions. 
In addition to HPV, several biomarkers have been suggested to foresee the prognosis of 
OSCC patients.  Knowing who the prognostic OSCC biomarkers are may be the first step to 
their arrival at the clinic. 
A key to the development of more effective therapy lies in a better understanding of the 
mechanisms involved in the progression of OSCC (Malik et al., 2016).  Tumors are encircled 
by extracellular matrix (ECM) (Wang et al., 2017). The ECM modulates the hallmarks of 
cancer, and changes in its dynamics contribute to tumor progression (Pickup et al., 2014). Some 
components of the ECM, which include heparan sulfate proteoglycans (HSPGs), are frequently 
overproduced in cancer (Lu et al., 2012). These molecules have a clinical potential for HNSCC 
(Farnedi et al., 2015). 
In a previous study, our group demonstrated that a HSPG called agrin induces OSCC 
cell adhesion and migration (Kawahara et al., 2014). In addition, agrin has been shown to act 
as a sensor in developing tumorigenic signals associated with the ECM in hepatocellular 
carcinomas (Chakraborty et al., 2015). These results suggested that agrin has an oncogenic role 
in oral cancer, furthermore, in the context of OSCC progression, there are no studies evaluating 
the role of agrin.  
In view of OSCC challenges set out in the content of this introduction, this doctoral 
thesis is aimed to i) identify, evaluate and summarize the evidence for reported prognostic 
biomarkers and ii) examine the role of agrin in the progression of this disease. 
This text was carried out in the alternative format, according to the Central Postgraduate 
Commission (CCPG/001/2015), University of Campinas. 
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ABSTRACT 
 
Over the years, several tumor biomarkers have been suggested to foresee the prognosis 
of oral squamous cell carcinoma (OSCC) patients. Here, we present a systematic review to 
identify, evaluate and summarize the evidence for OSCC reported markers. Eligible studies 
were identified through a literature search of MEDLINE/PubMed until January 2016. We 
included primary articles reporting overall survival, disease-free survival and cause-specific 
survival as outcomes. Our findings were analysed using REporting recommendations for tumor 
MARKer prognostic studies (REMARK), QuickGo tool and SciCurve trends. We found 41 
biomarkers, mostly proteins evaluated by immunohistochemistry. The selected studies are of 
good quality, although, any study referred to a sample size determination. Considering the lack 
of follow-up studies, the molecules are still potential biomarkers. Further research is required 
to validate these biomarkers in well-designed clinical cohort-based studies. 
 
Keywords. mouth neoplasms; oral cancer; oral squamous cell carcinoma; biomarkers, tumor; 
review, systematic 
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INTRODUCTION 
 
Oral squamous cell carcinoma (OSCC) is the most common malignancy of the head and 
neck (excluding nonmelanoma skin cancer), with more than 300,000 new cases reported 
annually worldwide[1]. The disease has a high morbidity rate (37.8%) five years after diagnosis 
(http://www.cancer.gov/statistics/find - 2003-2009 data); despite the progress in research and 
therapy, survival has not improved significantly in the last few decades [2]. The search for 
prognostic markers represents a continuing challenge for biomedical science. 
A cancer biomarker may be a molecule secreted by a tumor cell or a specific response 
of the body to the presence of cancer [3]. Biomarkers can be used for patient assessment in 
multiple clinical settings, including estimating the risk of disease and distinguishing benign 
from malignant tissues [4]. Cancer biomarkers can be classified based on the disease state, 
including predictive, diagnosis and prognosis biomarkers [5]. A prognostic biomarker informs 
about a likely cancer outcome (e.g., overall survival, disease-free survival, and cause-specific 
survival) independent of treatment received [6]. 
According to the NCI Dictionary of Cancer Terms 
(https://www.cancer.gov/publications/dictionaries/cancer-terms) the overall survival (OS) 
corresponds to the length of time from either the date of diagnosis or the start of treatment for 
cancer, which patients diagnosed with the disease are still alive. Disease-free survival (DFS, 
also called relapse-free survival) offers the length of time after primary treatment ends that the 
patient survives without any signs or symptoms of that cancer. Cause-specific survival (CSS) 
is the length of time from either the date of diagnosis or the start of treatment for cancer to the 
date of death from the disease. 
From the identification of a promising biomarker to its clinical use, there is a long 
pathway involving many complicated hurdles, such as estimating the number of patients needed 
for the validation phase and statistical validation, among others [7, 8]. This validation and 
qualification are responsible for linking the promising biomarker with a biological process to 
clinical endpoints [9]. 
Considering several tumor biomarkers have been suggested to predict the prognosis of 
OSCC patients, we performed a systematic review, which is widely accepted as a ”gold 
standard” in medicine based on evidence [10],  to identify, evaluate and summarize the evidence 
for OSCC reported markers. 
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METHODS 
 
We performed a systematic review to conduct this investigation. The independent 
variables were prognostic biomarkers; the dependent variables were OSCC outcomes. 
 
Search strategy. A systematic review allows critical analysis of multiple research 
studies. Aiming to answer the question “what are the biomarkers of OSCC?”, a systematic 
literature search based on keywords was performed. As PubMed comprises more than 26 
million citations from the biomedical literature from MEDLINE, it is the search engine of 
choice to initiate queries in the health sciences. To identify all the primary research studies that 
evaluated candidate biomarkers in OSCC, we searched the MEDLINE/PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) medical literature database up to January 18, 2016. The 
search strategy was based on combinations of the following keywords: “mouth neoplasms" 
[MeSH] and "biomarkers" [MeSH] and (risk ratio [Title/Abstract] or relative risk 
[Title/Abstract] or odds ratio [Title/Abstract] or risk [Title/Abstract]) and ("humans"[MeSH 
Terms] and English [lang]). 
 
Inclusion criteria. Articles were included based on a previously published protocol 
[11]. Briefly, studies were selected if they examined the impact of a potential biological marker 
on at least one of the features in OSCC patients: OS, DFS or CSS. These definitions were 
assessed among the selected papers. In addition, if a study was focused on isolated or combined 
(multiple) tumor biomarkers, it must have been subjected to multivariable analysis with one or 
more additional variables. 
 
Exclusion criteria. Articles were excluded from the present review for the following 
reasons: i) lack of the terms “oral cancer” and “risk” in their titles, abstracts or keywords; ii) 
absence of risk ratios and iii) unclear defining criteria for groups and variables. 
 
Potential prognostic biomarker. To determine whether a biomarker is potentially 
prognostic, the selected articles showed: i) a formal test (binary logistic regression or Cox 
proportional hazards model) and ii) a statistically significantly association between the 
biomarker and outcome [6]. The computed risk (odds ratio, OR or hazard ratio, HR) was 
reported as the risk of a specific outcome from the biomarker group versus the reference group, 
with OR/HR>1 indicating increased risk and OR/HR<1 indicating decreased risk.  
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Data extraction. One investigator reviewed all the eligible studies and carefully 
extracted the study characteristics, including the article citation information, biomarker name 
and classification, condition or outcome, laboratory technique, sample size, number of clinical 
outcomes, status of biomarker expression, statistical test method, computed risk and its p-value 
and 95% confidence interval (CI). The main biological processes in which the biomarkers are 
involved were obtained using QuickGo (http://www.ebi.ac.uk/QuickGO). 
 
Quality assessment.  Quality assessment was performed in duplicate for each eligible 
study by three independent reviewers using operationalized prognostic biomarker reporting the 
REMARK guidelines [12] and extracted details on 20 items. The inter-observer agreement was 
evaluated using Kappa statistics. 
 
Publication trends. To observe the publication trends in the selected potential OSCC 
biomarkers, we searched the scholarly literature in SciCurve Open (http://www.scicurve.com). 
SciCurve Open is a search engine that transforms a systematic literature review into an 
interactive and comprehensible environment [13]. 
 
RESULTS 
 
Studies searching for OSCC biomarkers: proteins are the most analysed molecules. 
The keyword search strategy identified 403 suitable abstracts, from which 320 were excluded 
by reviewing the title and abstract during the screen because they did not meet the eligibility 
criteria. Full text articles were obtained for 83 studies (34 with single markers and 49 with 
multiple or combined markers). 
Forty-five of these articles were excluded for different reasons, including: out of goal (3 
articles), unavailability online (2 articles), lack of multivariable analysis (18 articles) and model 
inconsistencies (22 articles). Figure 1 shows a PRISMA diagram for this review (for details, 
see Supplemental file S1, http://ars.els-cdn.com/content/image/1-s2.0-S1368837517301938-
mmc1.xlsx). 
The selected studies were screened, and specific study characteristics and remarks were 
recorded. These parameters are summarized in Table 1 (the article context is grouped according 
to the hallmarks of cancer [14]). Thirty-eight papers examined 41 biomarkers [15-52]. Most of 
them were proteins determined using immunohistochemistry (IHC) in paraffin-embedded 
tissues (36 of 38 studies). 
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The included studies were conducted in Poland, India, Germany, Taiwan, Korea, Japan, 
Australia, Spain, China, Portugal, Brazil, UK, USA and Finland. Variable cohort sizes were 
used, ranging from 34 to 208 patients. n, outcome event number, statistical test, CIs and p-
values, risk values and Google scholar citations were extracted (see Supplemental file S1). The 
main results of the included articles are summarized in Table 2. The biomarker high vs. low 
levels was defined differently in each study.  
Fourteen clinicopathologic group factors were incorporated in 48 multivariate analyses 
(38 studies generated 48 significant models and 210 covariables). The most commonly included 
prognostic factors for model adjustment were the histopathological features (excluding the 
WHO histological differentiation degree) in 30 models (62,5%), protein (27 models, 53,3%) 
AJCC clinical stage (22 models, 45,8%) and WHO histological differentiation degree (21 
models, 43,8%) (Figure 2). For complete details, see Supplemental file S1. 
 
Quality of study reports: studies do not clear determine the sample size. The result 
of this agreement was 0.87, which is classified as almost perfect. Differences were resolved by 
consensus. Most study analyses reported details of the objective/hypothesis, patient source, 
population characteristics, assay method, cut-off point, and relationship of the potential marker 
to standard prognostic variables, as well as discussed the implications for future research and 
clinical value (for details, see Supplemental file S2, http://ars.els-cdn.com/content/image/1-
s2.0-S1368837517301938-mmc2.xlsx). Notably, no study referred to a statistical sample size, 
which is key for biomarker validation. 
 
Proposed OSCC biomarkers. None of the studied molecules presented an analysis of 
validation, so we called them “potential biomarkers”.  A narrative review of the proposed 
biomarkers is presented in Table 3.  
 
Trends: potential biomarkers with more publications and citations. To explore the 
publication trends in our OSCC potential protein biomarkers, we searched the scholarly 
literature in SciCurve Open. SciCurve uses PubMed’s library of 23 million references to 
generate visually pleasing graphs and curves that help grasp trends in the literature [53].  It is 
associated with the following main functionalities: publications, citations, most prolific authors 
and countries.  
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According to Figure 3, MMP-2 is the most researched field, followed by MMP-1, 
cadherin-1 and mucin-1. The countries with the largest contributions are the USA, Japan and 
China. 
 
DISCUSSION 
 
We have summarized the results on the association between biomarkers and oral 
cancer outcomes using a systematic review. Overall, our results suggest 41 prognostic 
molecules involved with OSCC endpoints. These markers may be candidates for long-term 
studies. 
OSCC is the most relevant epithelial malignancy for dental surgeons. It has late clinical 
detection and poor prognosis, and the available therapeutic alternatives are highly expensive 
and disfiguring [54]. 
OSCC is a very complex subtype of cancer with high heterogeneity [55]. Several risk 
factors are implicated in its aetiology, among which tobacco, alcohol, viruses and diet are 
highlighted [2]. These factors related to genetic inheritance may have a carcinogenic effect on 
the normal cells of the respiratory and digestive systems. This type of carcinoma can occur 
anywhere in the mouth, although the most affected sites are the tongue, lower lip and mouth 
floor [2, 56]. These regions are great facilitators of carcinoma spreading to regional lymph 
nodes and/or distant organs [57]. At present, the diagnosis of OSCC is based on comprehensive 
clinical examination and histological analysis of suspicious areas [58]. Recently, The Cancer 
Genome Atlas (TCGA) showed that a large dataset of proteomics/genomics did not improve 
the prognosis potential of classic clinical variables in patients with different types of cancer 
[59]. Some studies seeking biomarkers in oral cancer are still in the discovery phase, requiring 
validation to be accepted in clinical practice.  
Currently, biomarkers are a subject of particular interest because they may represent the 
most important part in the diagnosis step. In the future, specific and personalised diagnostics 
can guide treatment against the disease and consequently improve the chance of curing the 
disease. 
In response to the need for tumor biomarkers for OSCC that can be readily evaluated in 
routine clinical practice, we performed a systematic review (PubMed keyword-base query) of 
the published literature to identify single or multiple biomarkers for OSCC outcomes: overall 
survival, disease-free survival, relapse-free survival and cause-specific survival. The main 
finding was the identification of 38 studies describing multivariate survival analysis for 41 
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biomarkers. From these articles, MMP-2, MMP-1, cadherin-1, mucin-1, GLUT-1 (SLC2A1), 
mucin-4, interleukin-8, HPV-16, EGFR and p53 have received great interest from the scientific 
community. Of these, up to now, it is accepted that the HPV status have a clinical utility [60], 
suggesting that HPV positive head and neck squamous cell carcinomas form a distinct clinical 
entity with better treatment outcome [61].  
The malignant progression to OSCC is characterized by the acquisition of progressive 
and uncontrolled growth of tumor cells. Predicting whether premalignant lesions will progress 
to cancer is crucial to make appropriate treatment decisions. The first detectable clinical 
changes that can indicate that an epithelium is on the way to establish OSCC is the occurrence 
of malignant disorders, including leukoplakia (most common) [2]. In this context, we 
emphasize the results associated with Rho GTPase-activating protein 7, retinal dehydrogenase 
1/prominin-1 (combined biomarkers), podoplanin, cortactin/focal adhesion kinase 1 (combined 
biomarkers) and catenin delta-1. These proteins show a potential role as a marker of oral cancer 
risk and  malignant transformation [17, 26-28, 39, 40, 42].  
There are thousands of papers reporting cancer biomarker discovery, but only few 
clinically useful biomarkers have been successfully validated for routine clinical practice [62]. 
Quality assessment tools have been developed for prognostic studies to help identify study 
biases and causes of heterogeneity when performing meta-analysis. We chose to use the 
REMARK reporting guidelines, which provide a useful start for assessing tumor prognostic 
biomarkers (all included studies were prognostic). We found that the investigations reported an 
average of 19 of 20 REMARK items. However, all studies failed to report the sample size 
calculation. In the absence of this calculation, the findings of each research should be 
interpreted with caution [63]. The sample size requirements that allow the identification of a 
benefit beyond existing biomarkers are even more demanding [64]. 
In our review, none of the articles that created prediction models had internal or external 
validation. In general, studies recruited cases of OSCC from a clinical setting as well as controls 
without a clearly defined diagnosis. Under this circumstance, any differences in the biomarker 
levels between OSCC patients and controls could simply reflect individual differences rather 
than cancer-related differences. The lack of biomarker validation strategies and standard 
operating procedures for sample selection in the included studies represent an important pitfalls 
and limitations, leading us to use the term "potential biomarkers". 
It is important to highlight that our research searched only one database, which means 
that only studies available in MEDLINE were included. Additionally, due to the heterogeneity 
among the studies, a meta-analysis that combined the results of different studies could not be 
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performed. In addition, our research included results from observational studies, and their 
evaluation may have been problematic if the confounder variables were not adjusted because 
they were not measured [65].  
 
CONCLUSION 
 
Recent research in OSCC has identified a multitude of potential markers that have a 
significant role in prognosis. In this systematic review, despite the inherent limitations, we 
identified several potential biomarkers of particular interest that appear to carry prognostic 
significance. Considering the validation step as a process of assessing the biomarker and its 
measurement performance characteristics, and determine the range of conditions under which 
this biomarker can provide reproducible data [9], our results show biomarkers in the discovery 
phase, thereby leading us to call them OSCC “potential biomarkers”. Nevertheless, it is urgent 
to apply validation methods to provide clinically useful oral cancer biomarkers. 
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Figure 1. Flow diagram representing systematic literature search on biomarkers and oral 
cancer outcomes. Studies were included if they examined the impact of a potential biomarker 
on at least one of overall survival, disease free survival or cause-specific survival in oral 
squamous cell carcinoma patients. 
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Figure 2. (A) Adjustment variables. Frequencies with which adjustments were 
performed for OSCC outcomes. The heat map combines the most frequent factors for 
adjustments and survival models. The most commonly included factor was “histopathological 
features” (excluding the WHO histological differentiation degree). Higher numbers represent 
intense and saturated colors. (B) Trends in oral cancer biomarkers (top ten). Compared with 
other biomarkers, MMP-2 is the most researched field with 15,057 publications and 46,368 
citations (1997-2017). MM-2 is followed by MMP-1 (14,650 publications/43,762 citations) and 
cadherin-1 (14,531/43,422).  
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Table 1. Characteristics of the included studies. 
 
Reference Biomarker* Change Design and 
method 
Study remarks 
Sustaining proliferative signaling 
Gontarz M et 
al., 2014 
Proliferation 
marker protein 
Ki-67 or ki-67 
(MKI67) 
(+) Poland. 
Retrospective. 
IHC. 
May be useful in the 
selection of patients at a 
higher risk of recurrence 
who would benefit from 
postoperative radiotherapy 
Ramshankar 
V et al. 2014 
Cyclin-
dependent kinase 
inhibitor 2A or 
p16 (CDKN2A) 
 
(+) India. 
Retrospective. 
IHC and RT-
qPCR. 
 
CDKN2A overexpression is 
a single important 
prognostic variable in 
defining a high risk group. 
CDKN2A expression should 
possibly not be used as a 
surrogate marker for HPV 
infection in tongue cancers. 
Human 
papillomavirus 
type 16 or HPV-
16 (HPV16) 
(+) 
Tripathi SC 
et al., 2012 
Rho GTPase-
activating 
protein 7 or 
DLC1 
(DLC1) 
(-) India. 
Retrospective. 
IHC. 
Loss of expression emerged 
as an important biomarker 
for predicting patients 
diagnosed with oral 
dysplasia at high risk of 
transformation. Is a poor 
prognostic marker for oral 
squamous cell carcinoma 
patients. 
Freudlsperger 
C et al., 2011 
MKI67 (+) Germany. 
Retrospective. 
IHC. 
 
Expression level could be 
used to identify a subgroup 
of surgically treated patients 
with stage I OSCC who 
might benefit from treatment 
intensification. 
Kok SH et 
al., 2010 
Protein CYR61 
(CYR61) 
(+) Taiwan. 
Retrospective. 
IHC. 
 
Is a positive growth 
modulator of OSCC and 
overexpression is an 
independent prognostic 
indicator. 
Shah NG et 
al. 2009 
Cellular tumor 
antigen p53 or 
p53 (TP53) 
(+) India. 
Retrospective. 
IHC. 
 
TP53 was independently 
associated with DFS and 
OS, and CDKN2A with DFS 
only.  CDKN2A 
 
(-) 
Kim SJ et al. 
2007 
Carbonic 
anhydrase 9 
(CA9) and  
MKI67 
combined 
(+) Korea. 
Retrospective. 
IHC. 
The expression of CA9 and 
MKI67may be useful for 
predicting prognosis in 
squamous cell carcinoma of 
the tongue. 
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Shiraki M et 
al. 2005 
 TP53, G1/S-
specific cyclin-
D1 (CCND1), 
epidermal 
growth factor 
receptor (EGFR) 
combined 
(+) Japan. 
Retrospective. 
IHC. 
 
Simultaneous expression of 
these markers in oral cancers 
might prove to be a useful 
indicator for identification of 
low- or high-risk patients. 
Myo K et al., 
2005 
 CCND1 (+) Japan. 
Retrospective. 
FISH. 
Aberrations in gene numbers 
appear to be valuable in 
identifying patients at high 
risk of late lymph node 
metastasis in stage I and II 
OSCCs.  
Pande P et al. 
2002 
TP53 (+) India. 
Prospective. 
IHC. 
 
RB1 loss and TP53 
overexpression may serve as 
adverse prognosticators for 
disease free survival of the 
patients. 
Retinoblastoma-
associated 
protein (RB1) 
(-) 
Bova RJ et 
al. 1999 
 CCND1 (+) Australia. 
Retrospective. 
IHC. 
 
CCND1overexpression and 
loss of CDKN2A expression 
predict early relapse and 
reduced survival in 
squamous cell carcinoma of 
the anterior tongue 
 CDKN2A (-) 
Evading growth suppressors 
Pérez-Sayáns 
M et al., 
2014 
Myc proto-
oncogene protein 
(MYC) 
(+) Spain. 
Retrospective. 
IHC. 
Its determination can be 
valuable when used together 
with other markers to assess 
the prognosis of OSCC 
patients. 
Liu W et al. 
2013 
Retinal 
dehydrogenase 1 
or ALDH1 
(ALDH1A1) 
(+) China. 
Prospective. 
IHC. 
 
Expression of cancer stem 
cell markers ALDH1A1 and 
PROM1 correlate with a 
high risk of malignant 
transformation in a large 
series of patients with 
premalignant oral 
leukoplakia. 
Prominin-1 or 
CD133 
(PROM1) 
(+) 
Feng JQ et 
al. 2013 
 ALDH1A1 (+) China. 
Retrospective. 
IHC. 
Expression pattern was 
associated with malignant 
transformation, suggesting 
that it may be valuable 
predictors for evaluating the 
risk of oral cancer. 
Suzuki F et 
al., 2005 
Protein S100-A2 
(S100-A2) 
(-) Japan. 
Retrospective. 
IHC. 
Patients with stage I or II 
invasive OSCC without 
expression should be 
considered a high-risk group 
for late cervical metastasis 
when a wait-and-see policy 
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for the neck is being 
considered. 
Tsai ST et 
al., 2005 
 S100-A2 (-) Taiwan. 
Retrospective. 
IHC. 
Loss of nuclear expression 
may serve as an independent 
prognostic marker for early-
stage oral cancer patients at 
high risk of recurrence. A 
more aggressive treatment 
modality and intensive 
follow-up may be 
recommended for the 
patients with reduced 
expression of in tumor cell 
nuclei. 
Resisting cell death 
Moura IM et 
al., 2014 
Cell division 
cycle protein 20 
homolog 
(CDC20) 
(+) Portugal. 
Retrospective. 
IHC. 
 
High expression is 
associated with poor 
prognosis in OSCC, may be 
used to identify high-risk 
OSCC patients, and may 
serve as a therapeutic target. 
 
Tang JY et 
al., 2013 
Microtubule-
associated 
proteins 1A/1B 
light chain 3A or 
LC3 
(MAP1LC3A) 
(+) Taiwan. 
Retrospective. 
IHC. 
 
Elevated expression, which 
corresponds to increased 
level of autophagy activity, 
is a frequent event and an 
indicator of poor prognosis 
in human OSCC. 
de Carvalho-
Neto PB et 
al. 2013 
Tumor necrosis 
factor receptor 
superfamily 
member 6 or 
FAS 
(FAS) 
(-) Brazil. 
Retrospective. 
IHC. 
DFS and CSS were 
significantly correlated with 
FAS/FASL expression 
profiles. The high risk 
category was an independent 
marker for earlier disease 
relapse and disease-specific 
death. 
Tumor necrosis 
factor ligand 
superfamily 
member 6 or 
FASL 
(FASLG) 
(-) 
Inducing angiogenesis 
Yanagawa T 
et al., 2004 
Heme oxygenase 
1 
(HMOX1) 
(-) Japan. 
Retrospective. 
IHC. 
Could be used clinically as a 
marker for tumors 
possessing the potential for 
lymph node metastasis. This 
method could prove useful 
as an adjuvant method to 
detect lymph node 
metastasis and may help 
reduce the number of 
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surgeries by indicating when 
surgery is unnecessary. 
Activating invasion and metastasis 
de Vicente 
JC et al., 
2013 
Podoplanin 
(PDPN) 
 
(+) Spain. 
Retrospective. 
IHC. 
Could be a valuable 
biomarker for risk 
assessment of malignant 
transformation in patients 
with oral leukoplakia along 
with histological assessment 
de Vicente 
JC et al. 2012 
Src substrate 
cortactin 
(CTTN) and 
focal adhesion 
kinase 1 (PTK2) 
combined  
(+) Spain. 
Retrospective. 
IHC. 
Strong immunoexpression of 
CTTN and PTK2, and not 
only one of them, is a 
predicting factor for 
increased cancer risk in oral 
premalignant lesions. 
Hamada T et 
al., 2012 
Mucin-4 
(MUC4) 
(+) Japan. 
Retrospective. 
IHC. 
Overexpression is an 
independent factor for poor 
prognosis of patients with 
OSCC; therefore, patients 
with OSCC showing 
positive expression should 
be followed up carefully. 
Ma LW et 
al., 2012 
Catenin delta-1 
(CTNND1) 
(+) China. 
Retrospective. 
IHC. 
May serve as a useful 
marker for the identification 
of a high risk of potentially 
malignant oral lesions 
progressing to OSCC 
Marsh D et 
al. 2011 
Actin, aortic 
smooth muscle 
or SMA 
(ACTA2) 
(+) UK. 
Retrospective. 
IHC. 
An positive, myofibroblastic 
stroma is the strongest 
predictor of OSCC 
mortality. 
Zhang Z et 
al. 2011 
Interstitial 
collagenase or 
MMP-1 (MMP1) 
(+) China. 
Retrospective. 
IHC. 
Up-regulation of MMP1, 
MMP2 might be important 
features of OSCC 
progression. 72 kDa type IV 
collagenase or 
MMP-2 (MMP2) 
(+) 
Liu LK et al. 
2010 
Vimentin (VIM) (+) China. 
Retrospective. 
IHC. 
The high expression of VIM 
and low expression of 
CDH1were associated with 
survival and were 
independent prognostic 
factors in multivariate 
analyses. 
Cadherin-1 
(CDH1) 
(-) 
Kawaguchi H 
et al., 2008 
 PDPN (+) USA. 
Retrospective. 
IHC. 
Together with histology, 
may serve as a powerful 
biomarker to predict the risk 
for oral cancer development 
in patients with oral 
leukoplakia. 
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Pukkila M et 
al., 2007 
VCAN protein 
(VCAN) 
(+) Finland. 
Retrospective. 
IHC. 
Correlated with both 
increased risk for disease 
recurrence and shortened 
survival. High stromal 
expression may thus be 
considered an independent 
and adverse prognostic 
marker in OSCC. 
Endo K et al. 
2006 
E3 ubiquitin-
protein ligase 
AMFR (AMFR) 
(+) Japan. 
Retrospective. 
IHC. 
Is valuable in identifying 
patients at high risk for 
tongue SCC recurrences 
Reprogramming of energy metabolism 
Hamada T et 
al., 2012 
Mucin-1 
(MUC1) 
(+) Japan. 
Retrospective. 
IHC. 
Is a risk factor for 
subsequent lymph node 
metastasis in patients with 
OSCC and therefore may 
represent an indication for 
elective neck dissection 
Eckert AW et 
al. 2011 
Hypoxia-
inducible factor 
1-alpha (HIF1A) 
or HIF-1α and 
Solute carrier 
family 2, 
facilitated 
glucose 
transporter 
member 1 or 
GLUT-1 
(SLC2A1) 
combined 
(+) Germany. 
Retrospective. 
IHC. 
Coexpression of high levels 
of HIF1A and SLC2A1 is 
significantly correlated with 
prognosis in OSCC patients. 
Eckert AW et 
al., 2010 
 HIF1A (+) Germany. 
Retrospective. 
IHC. 
Immunohistochemical 
detection appears to improve 
diagnosis and to provide 
prognostic information in 
addition to the TNM – 
system and histological 
grade of OSCC. 
Fillies T et 
al., 2005 
 HIF1A (-) Germany. 
Retrospective. 
IHC. 
Overexpression is an 
indicator of favorable 
prognosis in T1 and T2 SCC 
of the oral floor.  Node 
negative patients lacking 
expression may therefore be 
considered for adjuvant 
radiotherapy. 
Tumor-promoting inflammation 
Kwon M et 
al., 2015 
Interleukin-4 
receptor subunit 
alpha 
(+) Korea. 
Retrospective. 
IHC. 
High expression of IL4R 
correlated with increased 
recurrence, while high 
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(IL4R) IL13RA1 expression had an 
inverse relationship to 
recurrence and disease-
specific survival in OSCC 
patients. 
Interleukin-13 
receptor subunit 
alpha-1 
(IL13RA1) 
(+) 
Fujita Y et al. 
2014 
Interleukin-8 
(CXCL8) 
(+) Japan. 
Retrospective. 
IHC. 
These factors in addition to 
N status may have 
prognostic value in patients 
with resectable OSCC. 
Scavenger 
receptor 
cysteine-rich 
type 1 protein 
M130 
(CD163) 
(+) 
Lai WM et 
al. 2013 
Myeloperoxidase 
(MPO) 
(+) Taiwan. 
Retrospective. 
IHC. 
Higher MPO expression in 
buccal mucosal SCC is a 
risk factor for second 
primary tumors. 
Huang SF et 
al. 2012 
Serpin B3 
(SERPINB3) 
and C-reactive 
protein (CRP) 
combined 
(+) Taiwan. 
Retrospective. 
Immunoassay. 
High levels of both 
preoperative SERPINB3 and 
CRP levels act as a predictor 
for DFS and OS. 
The articles are grouped according to the hallmarks of cancer. *UniProt Knowledgebase 
or common name. HGNC name between parentheses. (+) Up-regulated/overexpressed, (-) 
Down-regulated/down-expressed, CSS, cause-specific survival;  OS, overall survival; DFS, 
disease free survival; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization. 
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Table 2. Data extracted from selected studies. 
 
Article Biomarker* N** Cases vs. 
reference group 
Outco
me 
HR CI p-
value 
Sustaining proliferative signaling 
Gontarz M et 
al., 2014 
MKI67 34 IHC. High vs. 
low. 
DFS 
CSS 
5.42 
9.02 
1.18–
24.83 
1.99–
40.93 
0.029 
0.004 
Ramshankar 
V et al. 2014 
CDKN2A 
 
156 IHC. 
Overexpression 
vs. low 
OS 
DFS 
2.34 
2.58 
1.30-
4.40 
1.44-
4.64 
0.005 
0.002 
HPV16 RT-qPCR. 
Negative vs. 
positive 
OS 0.61 0.38-
0.99 
0.049 
Tripathi SC 
et al., 2012 
DCL1 181 IHC. Loss vs. 
expression 
DFS 2.10 1.2-
3.9 
0.023 
Freudlsperger 
C et al., 2011 
MKI67 69 IHC. High vs. 
low  
DFS 4.24 NS. 0.029 
Kok SH et 
al., 2010 
CYR61 93 IHC. High vs. 
low 
OS 2.44 1.20–
4.95 
0.010 
Shah NG et 
al. 2009 
TP53 135 IHC. Positive vs. 
negative 
OS 
DFS 
2.71 
2.45 
1.29-
5.72 
1.28-
4.69 
0.009 
0.007 
CDKN2A IHC. Negative 
vs. positive 
DFS 2.08 1.05-
4.14 
0.036 
Kim SJ et al. 
2007 
CA9 and 
MKI67 
combined 
60 IHC. High vs. 
low 
OS 
DFS 
4.04 
2.39 
NS 
NS 
0.005 
0.007 
Shiraki M et 
al. 2005 
TP53, 
CCND1 and 
EGFR 
combined 
140 IHC. Co-
expression of all 
three markers vs. 
0-2 markers 
OS 3.56 1.59–
7.93 
0.002 
Myo K et al., 
2005 
CCND1 45 Numerical 
aberration 
positive vs. 
negative 
DFS 8.69 2.23–
33.80 
0.002 
Pande P et al. 
2002 
TP53 50 IHC. Positive vs. 
negative 
DFS 2.98 1.04-
8.47 
0.041 
RB1 IHC. Negative 
vs. positive 
DFS 2.94 0.12-
0.92 
0.034 
Bova RJ et 
al. 1999 
CCND1 147 IHC. Positive vs. 
negative 
DFS 2.48 1.0-
6.15 
0.005 
CDKN2A 143 IHC. Negative 
vs. positive 
OS 3.15 1.65-
7.50 
0.001 
Evading growth suppressors 
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Pérez-Sayáns 
M et al., 
2014 
MYC NA NA OS 1.15 1.06-
1.25 
<0.00
1 
Liu W et al. 
2013 
ALDH1A1 141 IHC. Positive vs. 
negative 
DFS 4.17 1.96–
8.90 
<0.00
1 
PROM1 IHC. Positive vs. 
negative 
DFS 2.86 1.48–
5.55 
0.002 
Feng JQ et al. 
2013 
ALDH1A1 34 IHC. Positive vs. 
negative 
DFS 8.89 
*** 
1.67–
47.41 
0.011 
Suzuki F et 
al., 2005 
S100-A2 52 IHC. Negative 
vs. positive 
DFS 0.20 0.08-
0.53 
0.001 
Tsai ST et 
al., 2005 
S100-A2 70 IHC. Low vs. 
high 
DFS 4.36 1.52-
12.49 
0.006 
Resisting cell death 
Moura IM et 
al., 2014 
CDC20 65 IHC. Positive vs. 
negative 
CSS 2.36 1.08–
5.17 
0.032 
Tang JY et 
al., 2013 
MAP1LC3A 90 High vs. low OS 2.99 1.39-
7.05 
0.004 
de Carvalho-
Neto PB et 
al. 2013 
FAS 60 IHC. Negative 
vs. positive 
DFS 3.73 1.16-
11.95 
0.027 
FASLG IHC. Negative 
vs. positive 
CSS 2.58 1.03-
6.46 
0.044 
Inducing angiogenesis 
Yanagawa T 
et al., 2004 
HMOX1 54 IHC. Low vs. 
high 
DFS 8.49*
** 
1.64-
44.09 
0.010 
Activating invasion and metastasis 
de Vicente 
JC et al., 
2013 
PDPN  58 IHC. Score  2–3 
vs. 0–1 
 
DFS 8.74 
 
1.83-
41.63 
0.007 
de Vicente 
JC et al. 2012 
CTTN and 
PTK 
combined  
50 IHC. High co-
expression of vs. 
negative to 
moderate 
DFS 6.30 1.55-
25.58 
0.01 
Hamada T et 
al., 2012 
MUC4 150 IHC. Positive vs. 
negative  
OS 1.62 1.12-
2.41 
0.002 
Ma LW et 
al., 2012 
CTNND1 68 Phosphorylated. 
IHC. High vs. 
low 
DFS 3.43 1.40-
8.41 
0.007 
Marsh D et 
al. 2011 
ACTA2 208 IHC. High vs. 
low 
OS 3.06 1.65-
5.66 
0.002 
Zhang Z et 
al. 2011 
MMP1 NS. IHC intensity in 
cancer tissue 
(continuous 
variable) 
DFS 1.09 
*** 
1.03-
1.16 
0.003 
MMP2 IHC intensity in 
cancer tissue 
(continuous 
variable) 
DFS 1.03 
*** 
1.00-
1.05 
0.025 
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Liu LK et al. 
2010 
VIM 83 IHC. High vs. 
negative/low 
OS 1.61 1.02-
2.55 
0.042 
CDH1 IHC. 
Negative/low vs. 
high 
OS 0.58 0.37-
0.90 
0.016 
Kawaguchi H 
et al., 2008 
PDPN 150 IHC. Oral 
leukoplakia 
positive vs. 
negative 
DFS 3.09 1.53-
6.23 
0.002 
Pukkila M et 
al., 2007 
VCAN 
 
139 IHC. High vs. 
low 
CSS 1.80 1.01-
3.30 
0.048 
Endo K et al. 
2006 
AMFR 99 IHC. Positive vs. 
negative 
DFS 2.07 1.04-
4.11 
0.038 
Reprogramming of energy metabolism 
Hamada T et 
al., 2012 
MUC1 206 IHC. Positive vs. 
negative 
 
OS 
DFS1 
DFS2 
2.09 
1.71 
2.29 
1.04-
4.29 
1.02-
2.85 
1.08-
4.93 
0.040 
0.040 
0.030 
Eckert AW et 
al. 2011 
HIF1A and 
SLC2A1 
combined 
55 IHC. High co-
expression vs. 
low 
CSS 5.13 1.33–
19.79 
0.017 
Eckert AW et 
al., 2010 
HIF1A 80 IHC. Moderate 
or strong vs. 
negative or weak 
CSS 3.49 NS 0.016 
Fillies T et 
al., 2005 
HIF1A 85 IHC. Low vs. 
very high 
OS 
DFS 
0.20 
0.30 
0.10–
0.50 
0.10–
0.70 
0.000 
0.010 
Tumor-promoting inflammation 
Kwon M et 
al., 2015 
IL4R 186 IHC. High vs. 
low 
DFS 2.34 1.38-
3.97 
0.002 
IL13RA1 IHC. High vs. 
low 
OS 
DFS 
0.26 
0.33 
0.14-
0.48 
0.17-
0.67 
<0.00
1 
0.002 
Fujita Y et al. 
2014 
CXCL8 50 IHC. Positive vs. 
negative 
DFS 0.27 0.08-
0.89 
0.031 
CD163  IHC. Invasive 
front, high vs. 
low 
DFS 2.63 1.31-
5.25 
0.006 
Lai WM et 
al. 2013 
MPO 173 IHC. High vs. 
low 
DFS 3.89 1.33-
11.39 
0.013 
Huang SF et 
al. 2012 
SERPINB3 
and CRP 
combined 
99 Immunoassay. 
Positive vs. 
negative 
DFS 
OS 
8.43 
6.25 
3.94-
18.01 
2.60-
15.01 
<0.00
1 
<0.00
1 
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The articles are grouped according to the hallmarks of cancer. *HGNC database 
recommended names were used. **N, number of subjects in the contrast. ***Odds ratio 
(multiple logistic regression). HR and OR values are reported as they originally appear in the 
selected articles. NS, not specified. NA, not apply. DFS, disease free survival; CSS, cause-
specific survival; OS, overall survival;. 1Recurrence and 2lymph node metastasis. 
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Table 3. Overview of proposed biomarkers 
 
Name* Biological 
processes 
Cancer context 
MKI67 Cell cycle, cell 
proliferation. 
Marker of the growth fraction for a certain cell 
population [66]. The labelling index is considered 
one of the best prognostic factors of the survival rate 
and recurrence [56]. 
CDKN2A Cell cycle, cell 
cycle arrest. 
This gene is frequently mutated or deleted in a wide 
variety of tumors, and is known to be an important 
tumor suppressor gene [67]. 
HPV16 High-risk HPV type. Is emerging as an important factor in the rise of 
oropharyngeal tumors affecting non-smokers in 
developed countries. Patients with HPV(+) tumors 
demonstrated favorable outcomes compared to TP53 
mutants and 11q13/CCND1-amplified tumors [60]. 
DLC1 Negative regulation 
of cell proliferation 
and migration. 
Acts as a tumour suppressor in a number of common 
cancers, including liver cancer [68]. 
CYR61 Regulation of cell 
growth and 
adhesion. 
Can function as an oncogene or a tumour suppressor, 
depending on the origin of the cancer [69]. 
TP53 Cell cycle, cell 
cycle arrest. 
Tumor-suppressor protein. Mutations in this gene are 
associated with a variety of human cancers [67]. 
CA9 Response to 
hypoxia. 
Is the most widely expressed gene in response to 
hypoxia. Its role in intracellular pH maintenance 
represents the means by which cancer cells adapt to 
the toxic conditions of the extracellular environtment 
[70] 
CCND1 Cell cycle, cell 
division. 
Is frequently deregulated in cancer and is a biomarker 
of cancer phenotype and disease progression [71]. 
EGFR Positive regulation 
of cell proliferation. 
EGFR overexpression is a significant finding in 
cancer, particularly in head and neck cancer, where it 
is also associated with a poor prognosis [72].   
RB1 Cell cycle, cell 
cycle arrest. 
Tumor-suppressor protein. Defects in this gene are a 
cause of childhood cancer retinoblastoma (RB), 
bladder cancer, and osteogenic sarcoma [67]. 
MYC Positive regulation 
of cell proliferation. 
Its oncogenic reputation stems from its frequent 
deregulation in a host of human cancers and from a 
suite of activities that place this protein at the nexus 
of cell growth, proliferation, metabolism, and 
genome stability [73]. 
ALDH1A1 Ethanol oxidation. Play a key role in the regulation of growth and 
differentiation of both normal tissue stem cells and 
cancer stem cells [74]. 
PROM1 Retina layer 
formation. 
Maintaining stem cell properties by suppressing 
differentiation [67]. 
S100-A2 Endothelial cell 
migration. 
In epithelial tissue, S100-A2 expression is decreased 
remarkably in tumours compared with normal 
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specimens [75]. S100-A2 promotes p53 
transcriptional activity, and its loss of expression has 
been associated with a poorer prognosis and shorter 
survival [76].  
CDC20 Cell cycle, positive 
regulation of cell 
proliferation. 
The role of CDC20 expression in tumours is not 
known, but many studies have reported that CDC20 
regulates apoptosis, leading to genetically instability 
[77] 
MAP1LC3A Autophagy. Strong positive expression in the peripheral area of 
pancreatic cancer tissue had a shorter overall and 
disease-free survival; correlations with tumour size, 
poor differentiation, blood vessel infiltration and 
tumour necrosis were noted [78]. 
FAS Apoptotic process. Cancer cells can never lose FAS or FASLG. FAS 
and/or FASLG expression promotes tumor growth 
and favors the establishment of tumor metastases 
[79].  
FASLG 
HMOX1 Angiogenesis. Many human tumours produce HMOX1, and its 
expression is usually higher in cancer cells than in 
surrounding healthy tissues [80]. 
PDPN Lymphangiogenesis. Is commonly used in the identification of lymphatic 
endothelial differentiation in vascular endothelial 
neoplasms and lymphatic invasion by tumours [81]. 
Recent evidence have identified podoplanin as a 
marker of cancer-associated fibroblasts [82]. 
CTTN Cell motility and 
focal adhesion 
assembly. 
Is overexpressed in breast cancer and squamous cell 
carcinomas of the head and neck [67]. 
PTK2 Angiogenesis. Promotes tumor progression and metastasis through 
effects on cancer cells, as well as stromal cells of the 
tumor microenvironment [83] 
MUC4 Cell adhesion. An aberrant expression of MUC4 has been reported 
in various carcinomas [84].  
CTNND1 Cell adhesion. Evidence is emerging that complete loss, 
downregulation or mislocalization of CTNND1 
correlates with the progression of different types of 
human tumours [85]. 
ACTA2 Mesenchyme 
migration. 
Patients with lung adenocarcinomas and high 
ACTA2 expression showed significantly enhanced 
distant metastasis and unfavorable prognosis [86]. 
MMP1 Proteolysis. Imbalance between matrix metalloproteinases and 
their inhibitors play the important role in progression 
of head and neck cancer [87]. 
MMP2 Angiogenesis, 
response to hypoxia 
and proteolysis. 
VIM Movement of cell or 
subcellular 
component. 
Has been recognized as a marker for epithelial-
mesenchymal transition. Overexpression in cancer 
correlates well with accelerated tumor growth, 
invasion, and poor prognosis [88]. 
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CDH1 Cell adhesion. Loss of function of this gene is thought to contribute 
to cancer progression by increasing proliferation, 
invasion, and/or metastasis [67]. 
VCAN Cell adhesion. Is strongly associated with a poor outcome for many 
different cancers. Depending on the cancer nature, is 
expressed either by cancer cells themselves or by 
stromal cells surrounding the tumour [89].  
AMFR Movement of cell or 
subcellular 
component. 
Is a tumor motility-stimulating protein secreted by 
tumor cells [67]. 
MUC1 DNA damage 
response, signal 
transduction by p53 
class mediator 
resulting in cell 
cycle arrest 
Is aberrantly glycosylated and overexpressed in 
various epithelial cancers and plays a crucial role in 
the progression of the disease [90]. MUC1 is often 
used as a diagnostic marker for metastatic 
progression [91].  
 
HIF1A Angiogenesis, 
response to hypoxia. 
Up-regulates the expression of proteins that promote 
angiogenesis, anaerobic metabolism, and many other 
survival pathways [92].  
SLC2A1 Glucose transport. Was significantly correlated with depth of invasion 
and clinical stage in patients with gastric cancer [93]. 
IL4R Immune system 
process and 
regulation of cell 
proliferation 
The IL4/IL4R signaling axis is a strong promoter of 
pro-metastatic phenotypes in epithelial cancer cells 
including enhanced migration, invasion, survival, and 
proliferation [94]. 
IL13RA1 Cell surface 
receptor signaling 
pathway. 
Glioblastoma samples presented higher IL13RA1 and 
IL13RA2 expression levels compared to lower grades 
astrocytomas and non-neoplastic cases [95]. 
CXCL8 Angiogenesis, 
movement of cell or 
subcellular 
component and 
chemotaxis 
Neovascularisation is now recognised as a critical 
function of CXCL8 in the tumour microenvironment 
[96]. 
CD163 Inflammatory 
response. 
Could be used as a general anti-inflammatory 
myeloid marker with prognostic impact for breast 
cancer patients [97]. 
MPO Defense response. Myeloperoxidase-positive cell infiltration in 
colorectal carcinogenesis is an indicator of colorectal 
cancer risk [98]. 
SERPINB3 Positive regulation 
of cell proliferation. 
Promotes oncogenesis and epithelial-mesenchymal 
transition [99] 
CRP Inflammatory 
response. 
Patients with a high baseline CRP had a greater risk 
of early death compared with those with low CRP 
levels [100]. 
*HGNC database recommended names were used. **Representative processes from 
QuickGo (http://www.ebi.ac.uk/QuickGO). 
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ABSTRACT 
 
Oncogenic processes that could associate agrin and oral cancer have been identified, but 
these findings have not been observed in the context of oral cancer progression. Here, we show 
that silencing agrin interferes with OSCC tumor progression, both in vitro and in vivo. Agrin 
silencing suppressed cancer progression-associated events, including cell migration, 
proliferation, invasion, colony and tumor spheroid formation, and it also decreased the mRNA 
levels of the OSCC oncogene, EGFR. In a mouse orthotopic model, silencing of agrin reduced 
tumor severity in terms of ulceration, growth pattern and vascular and neural invasion. To gain 
insights into interaction partners in the agrin complex, we expressed its soluble C-terminus 
(which has been identified as a potential marker for colorectal cancer), and we identified that 
its protein network predicts a poor clinical prognosis. Together, our results demonstrate that 
agrin is important for oral cancer-associated events and is a strong candidate as a therapeutic 
target for OSCC.  This study deepens the understanding of the pathophysiological role of agrin 
in oral cancer progression. 
 
Keywords. agrin; head and neck neoplasms; mouth neoplasms; oral cancer; biomarkers; tumor; 
proteomics; protein interaction maps 
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INTRODUCTION 
 
Worldwide, head and neck squamous cell carcinoma (HNSCC) affects over 500,000 
patients per year [1]. Oral squamous cell carcinoma (OSCC) represents 95% of all forms of 
HNSCC [2]. It is the most common malignancy of the head and neck [3]. Despite advancements 
in prevention and multimodality therapies, the prognosis of OSCC patients has remained 
unfavorable in the last few decades [4,5]. A better understanding of the cellular and molecular 
mechanisms that promote the progression of OSCC can help improve our approach to this 
disease. 
The process of cancer progression (i.e., local invasion and metastasis) is characterized 
by rapid cellular growth accompanied by alterations of the microenvironment of the cancer cells 
[6]. The extracellular matrix (ECM) modulates the hallmarks of cancer, and changes in its 
dynamics contribute to tumor progression [4]. Some components of the ECM, which include 
heparan sulfate proteoglycans, are frequently overproduced in cancer [7]. Agrin is one of the 
main heparan sulfate proteoglycans present in the ECM.  
Agrin is a multi-domain protein expressed as either a membrane protein or secreted in 
the ECM [8]. The best characterized function of agrin is in synaptic stabilization during 
development of the neuromuscular junction [9,10]. Agrin has been shown to act as a sensor in 
developing oncogenic signals associated with the ECM in hepatic carcinomas [8]. In a previous 
study, we demonstrated that agrin induces OSCC cell adhesion and migration [11], suggesting 
that agrin also has an oncogenic role in oral cancer. 
Agrin can be proteolytically cleaved, which generates bioactive fragments that modulate 
cellular behavior [12]. One of the agrin cleavage products, the C-terminal fragment (hereafter 
called Ct-agrin), has been shown to be a promising new biomarker for pathological processes 
including sarcopenia [13,14], renal dysfunction [15,16] and colorectal cancer [17]. Within 
OSCC are proteases, such as MMP-3 and neurotrypsin [18,19], that are capable of generating 
this soluble fragment. 
Despite the findings from the aforementioned studies, the contribution of agrin to OSCC 
remains unknown. Furthermore, in the context of OSCC progression, there are no studies 
evaluating the role of agrin or Ct-agrin. To better understand the role of this protein in OSCC, 
we modulated the expression of agrin in aberrant keratinocytes and evaluated processes and 
characteristics associated with cancer progression in vitro and in vivo. Considering the potential 
of Ct-agrin, we identified its binding proteins in an OSCC context using mass spectrometry-
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based proteomics and bioinformatics tools. Finally, we demonstrated the prognostic relevance 
of agrin and its protein network using publicly available cancer databases.  
 
METHODS 
 
Ethical statement. These procedures were in accordance with the Helsinki Declaration and the 
guidelines for the welfare and use of animals in cancer research [20]. This research was 
approved by the Institutional Animal Ethics Committee (CEUA/CNPEM), protocol #13/2015. 
 
Theoretical assumptions. a) If the silencing of a gene inhibits the processes that are essential 
for malignant progression, this gene and its product could represent potential therapeutic 
targets. b) The disintegration of the basement membrane upon local invasion processes can 
release agrin processing products such as Ct-agrin [17]. Ct-agrin is a biomarker for several 
pathological processes. Oral cancer tumors have proteases that are capable of generating this 
bioactive fragment. Focusing on the dynamics of tumor progression, we believe that Ct-agrin 
can help explain the role of agrin in oral cancer. c) A majority of proteins interact with others 
in order to carry out their functions [21]. We consider that the role of a protein can be explored 
by knowing the function of its associated proteins. 
 
General design. Figure 1 shows the main steps in this study. In the first experiment, we 
investigated whether silencing agrin interferes with tumor growth and expansion. The results 
in cells and mice showed that the blockage of agrin expression reduces both tumor progression 
and severity of the lesions. However, we did not have information on the mechanisms behind 
these results. We assumed that Ct-agrin could help explain these findings. Next, in order to 
better understand the role of agrin, we identified the protein network associated with Ct-agrin. 
Finally, we evaluated the clinical relevance of agrin and its network. 
 
Subjects. 
 
Cells. The following cell lines were used: HMK and HaCaT (normal keratinocytes), SCC-9 and 
SCC-25 (OSCC), HSC-3 and SCC-9-LN1 (metastatic OSCC), and HEK-293 (variable 
tumorigenic potential [22]. Culture conditions are summarized in the Supplement. 
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Mice. Age matched NOD-SCID male mice (6–weeks old) were obtained under specific 
pathogen-free conditions (FMUSP, São Paulo, Brazil). Animals were maintained under 
controlled conditions (photoperiod of 12:12 light/dark cycle at 21–24°C) with freely available 
food and water, in groups of 4 mice, in polycarbonate cages enriched with sterilized tissue 
paper.  
 
Procedures. 
 
Generation of agrin silenced cells. We performed agrin (isoform 1, also known as secreted 
agrin) silencing studies using short hairpin RNA (shRNA)-expressing vectors (Supplement). 
We generated the following two cell groups: agrin silenced cells (shAgrin) and non-silencing 
control cells (shControl). Agrin silencing was verified by real-time quantitative PCR (RT-
qPCR) and western blot. 
 
Generation of C-terminal agrin-overexpressing cells. We simulated a secreted bioactive 
fragment of agrin using the C-agrin4,19-GFP construct [23] (Ct-agrin; Supplement). We used a 
FLAG-tagged GFP (named Ip-control) vector as a control. The Ct-agrin vector produced 
cytotoxicity in SCC-9 and HSC-3 cells (Supplementary Figure 1A). We solved this problem by 
transfecting HEK-293 cells over 48 h (Supplementary Figure 1B). 
 
Gene expression analysis. We performed RT-qPCR. Total RNA was extracted, and cDNA 
was synthesized. RT-qPCR reactions were performed using SYBR Green PCR Master Mix 
(Applied Biosystems). Relative mRNA quantification was obtained with the 2−ΔΔ Ct method 
[24] using the glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH) as a reference (see 
supplement for further details). 
 
Immunoblotting detection. We verified the presence of agrin by western 
blotting. Procedures for protein extraction can be reviewed in the Supplement. Cell lysate 
and secretome extracts were separated by 10% SDS-PAGE and transferred onto a 
nitrocellulose membrane, which was blocked in 5% skimmed milk in TBST overnight, 
followed by incubation with the primary anti-agrin antibody (1:500 dilution) and the 
appropriate secondary antibody conjugated with horseradish peroxidase. We visualized 
immunoreactive bands by chemiluminescence. 
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Agrin and cancer-associated events. 
 
Proliferation. We plated 1x104 cells/well in 96-well plates. Proliferation rates were determined 
by measuring BrdU incorporation into DNA (Cell Proliferation ELISA BrdU Colorimetric, 
Roche Applied Science) following the manufacturer’s protocol. Absorbance was measured at 
450 nm with correction at 690 nm. 
 
Migration and tumor cell invasion activity. We performed motility assays using 24-well 
chambers with uncoated 8-mm pore polycarbonate membranes (for migration) or 96-well 
chambers pre-coated with Matrigel Basement Membrane Matrix (for invasion; BD 
Biosciences). The chambers were rehydrated in a serum-free medium. A complete medium with 
10% FBS served as a chemoattractant in the bottom chamber. Next, 7.4×104 (for migration) 
and 8×104 (for invasion) cells/well were incubated for 24 h. At the end of the assays, cells 
invading the membrane or Matrigel were stained with 1% toluidine blue/1% borax solution. 
The dye was eluted using 1% SDS. Absorbance was measured at 620 nm. 
  
Cancer colony formation. We seeded 5×103 cells/well in six-well plates. The culture medium 
was changed every 2 days. After 9 days, cells were stained with 4% formaldehyde/0.005% 
gentian violet solution. Images were captured with an inverted microscope. We quantified 
colonies using ImageJ histogram (darkest) tool. 
 
Circulating tumor cells. To simulate cancer cells in the blood or lymphatic circulation, we 
performed a three-dimensional tumorsphere culture. We cultured 6x105 cells/dish in culture 
plastic wares with a non-adhesive surface, as described previously [25]. The multicellular 
tumorsphere area was analyzed using the ImageJ particle analysis tool. 
 
In vivo tumorigenesis and aggressiveness of lesions. We utilized an orthotopic model of 
OSCC. Mice were randomly divided into the following 2 groups (n=8 animals in each): HSC-
3 shControl and HSC-3 shAgrin. Then, 2.5 × 105 cells/tongue in 20 μL of Matrigel were 
intrabuccally implanted into the right lateral portion of the tongue. Animal health was 
monitored daily. After 21 days, tumor aggressiveness was established by presence of 
ulcerations and histopathological examination with a conventional hematoxylin-eosin 
technique. In a blinded fashion, we evaluated the growth pattern, keratinization, cell 
morphology, angiogenesis, and vascular (intravascular tumor thrombus) and neural invasion. 
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Determination of agrin binding partners. 
 
Immunoprecipitation. We used the secretome extract of Ct-agrin and IP-control cells. 
Immunoprecipitation was performed at 4°C with 2.5 μg of GFP antibody (#af4240, R&D 
Systems) in the presence of 30 µL of protein G-Sepharose 4 Fast Flow (GE Healthcare) for 2 h 
in a rocker. Sample proteins of 250 μg were added and incubated with the beads overnight at 
4°C. The sepharose-bound proteins were washed with cold TBTS. Bound proteins were eluted 
with 4X Laemmli sample buffer at 95°C for 10 min and resolved by SDS–PAGE for subsequent 
western blotting (Supplementary Figure 1C). 
 
Protein identification. From 3 biological replicates, we excised, reduced, alkylated, trypsin-
digested and desalted 60 SDS-PAGE gel bands containing soluble proteins of agrin complexes 
according to previous protocols [26] (Supplementary Figure 1C). Tryptic digested peptides 
were identified in an LTQ Velos Orbitrap mass spectrometer (Thermo Fisher Scientific Inc.) 
according to our previous protocols [26]. Identification of proteins was performed using 
MaxQuant v1.5 [27] and Perseus [28] v1.5, as described previously [29]. See Supplement for 
further details. For bioinformatics, we focused on proteins identified exclusively in the Ct-agrin 
group. 
 
Agrin network characterization. 
 
Cellular model validation. We used the Integrated Pathway Analysis Database for Systematic 
Enrichment Analysis (IPAD) [30]. IPAD was useful to validate inter-association between our 
identified proteins list and diseases. We considered the model validated if oral cancer appeared 
within the top 10 ranked diseases. 
 
Protein-protein interactions. We assigned numeric values to all identified proteins as 
follows: -3 (Ip-control exclusive proteins), +3 (Ct-agrin exclusive proteins) and 1 (common 
proteins). Networks were visualized using the Contextual Hub Analysis Tool (CHAT app) for 
Cytoscape v3.4. software [31]. First, neighbor interactors were sourced from 4 databases 
(InnateDB-all, Mentha, IntAct, and UniProt). Then, we identified the most important centers of 
activity (top 20 contextual nodes, hereafter called hubs). To prioritize proteins, we used the 
cBio cancer genomics portal [32]. We chose those proteins that presented any alteration in a 
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percentage equal to or higher than 20% of the Cancer Genome Atlas HNSCC sample (TCGA 
2015, n=279) [33] (Supplementary Figure 1C).  
 
Network description. We used the STRING database [34] to retrieve the predicted interactions 
for the prioritized proteins. STRING v10.5 gives an association score for two interacting 
proteins. A high score indicates greater association confidence. We further described the 
proteins using QuickGO [35]. We evaluated the gene expression levels of the agrin network in 
agrin silenced and control cells. 
 
Prognostic potential. We compared the gene expression levels of the agrin network in 
microarray data sets (OSCC vs normal tissues) using Oncomine [36]. We defined the threshold 
for the P-value and fold change as 1E-4 and 2, respectively. The rank for a gene is the median 
rank for that gene across each of the analyses. Additionally, we studied differential protein 
IHC staining in HNSCCs using protein data from the Cancer Atlas (TCGA 2015, n=279) [37]. 
We consulted the PROGgene online tool [38] to determine the prognostic value of the agrin 
network in HNSCCs. We used the GSE65858 dataset (n=269) [39] to analyze overall survival 
(adjusted to clinical stage). 
 
Statistical analysis. All independent experiments were performed in triplicate. We presented 
the results as the mean ± standard deviation (SD). We analyzed differences between groups 
using Chi-Square, Student’s t-test, Fisher’s exact and one-way ANOVA (with post hoc Tukey) 
tests. PROGGene was used to create survival curves using the Cox survival analysis. In all the 
procedures, we used a 95% confidence level (P-value ≤0.05). 
 
RESULTS 
 
Agrin silencing suppresses cancer progression events. Most oral cancer cell lines secreted 
high levels of agrin (Figure 2A, right panel). We used shRNA technology to knockdown 
agrin expression in 3 cell lines. The knockdown efficiency of agrin shRNA was confirmed 
by RT-qPCR and dot blot (Figure 2B). Compared to non-target shRNA, treatment with agrin 
shRNA resulted in a significant decrease in cell proliferation, migration, invasion and mRNA 
levels of the OSCC oncogene, EGFR. (Figure 2C). In addition, agrin silencing suppresses 
the colony and tumor spheroids formation ability of OSCC cell lines (Figure 2D and E). 
Normal cells were unaffected by agrin silencing. 
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Agrin silencing reduces tumor aggressiveness. As shown in Figure 3A (right panel), mice 
that received agrin silenced cells (shAgrin) developed less aggressive tumors. These tumors did 
not have ulcers, presenting as a well-defined mass. According to histopathological examination, 
the shAgrin group produced tumors with few instances of vascular and nervous invasion (Figure 
3B). The characteristics of tumors generated from control cells show significantly greater 
severity in comparison to tumors originating from agrin silenced cells. An additional panel of 
histological images can be seen in Supplementary Figure 2. 
 
Agrin network. After the immunoprecipitation experiments (agrin construction is shown in 
5A), the proteins contained in the immune complexes of secreted agrin were identified using 
mass spectrometry (Dataset, http://www.oraldiseases.org/research/agrindataset.xlsx). We 
validated all identifications using IPAD enrichment. As shown in Figure 5B, tongue neoplasms 
are in the top 5 predicted protein-disease relationships. Then, we used the CHAT app and cBio 
portal to prioritize some proteins (Supplementary Figure 1C). We selected the following 9 
proteins: cullin-1 (CUL1), cullin-5 (CUL5), eukaryotic initiation factor 4A-II (EIF4A2), protein 
NDRG1 (NDRG1), polyadenylate-binding protein 1 (PABPC1), dolichyl-
diphosphooligosaccharide-protein glycosyltransferase subunit 1 (RPN1), double-stranded 
RNA-binding protein Staufen homolog 1 (STAU1), titin (TTN), and 14-3-3 protein zeta/delta 
(YWHAZ). Henceforth, we referred to agrin and its 9 partners as the "agrin network". STRING 
analysis resulted in a network with a clustering coefficient of 0.5 (PPI enrichment P-value 
0.037). The strategy resulted in 2 clusters (Supplemental Figure 1C). Most representative GO 
terms for cellular components and molecular function categories are presented in Figure 5C. 
Additional information can be reviewed in Dataset. 
 
High expression of agrin network predicts adverse prognosis. Agrin partners diminished 
their gene expression when agrin was silenced (Figure 5D). Further, an analysis of the agrin 
network across 9 Oncomine data sets revealed its upregulation (Figure 5E), which is quite 
similar to the trend observed in our RT-qPCR data. Head and neck cancers displayed moderate 
to strong agrin network immunoreactivity (Figure 5F). A high expression of agrin network is 
associated with lower overall survival rates in patients with head and neck cancer (hazard ratio 
7.6, confidence interval 1.7-33.3, P-value ≤ 0.05) (Figure 5G). 
 
 
 
60 
 
DISCUSSION 
 
A class of molecules with relevant clinical potential, particularly for HNSCC, is heparan 
sulfate proteoglycans [40]. They can be found on the cell surface and in the ECM. Research on 
these molecules as participants in cancer progression is fundamental and reveals complex 
relationships occurring at the microenvironment, cellular and subcellular levels [41]. In this 
study, we show that agrin promotes the progression of oral cancer and that its protein network 
predicts a poor clinical prognosis. 
Here, we present evidence demonstrating that the silencing of agrin leads to changes in 
oncogenic cell functions (proliferation, migration, invasion, and EGFR expression). Treatment 
with shRNA for agrin did not interfere with proliferation and migration functions in normal 
keratinocytes that were used as controls. This selectivity could open a window for therapeutic 
proposals.  
A previous study from our group showed that agrin can mediate migration and adhesion 
in oral cancer [11], and we demonstrated that agrin-silenced tumor cells showed a loss of 
capacity for proliferation, invasion and formation of cell agglomerates. Similarly, in the context 
of hepatic cancer, in which agrin is overexpressed, agrin promotes proliferation, invasion and 
oncogenic cellular signs [8]. These invasive and proliferative phenotypes constitute 
fundamental biological activities for the progression of a malignant neoplasia [42], and agrin 
contributes to maintaining these behaviors. In addition, the tumors generated by agrin-silenced 
cells in the OSCC orthotopic model exhibited reduced severity, both macro- and 
microscopically, showing less vascular and neural invasion, which are associated with a better 
clinical prognosis [3,43].  
We further interrogated the signaling pathways of agrin using the soluble C-terminal 
region of agrin once we verified the presence of cleaved or secreted agrin in oral cancer cell 
secretomes but not in normal cells. Combining immunoprecipitation followed by mass 
spectrometry-based proteomics and bioinformatics tools, we prioritized nine proteins that were 
involved in the agrin network, four of which were identified in the complex.  
Interestingly, the network proteins were associated with specific cancer events and 
showed a high clustering coefficient (0.5), representing a biologically connected community, 
which was confirmed by changes in gene expression in OSCC cells when agrin was silenced. 
CUL1 and CUL5 provide a scaffold for ubiquitin ligases. They participate in the processes of 
ubiquitylation and neddylation, which lead to the degradation of tumor-suppressor proteins 
[44]. RPN1 forms part of the ubiquitin proteasome system. It is a structural component of the 
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proteasome [45]. EIF4A2 boosts the malignant phenotype in solid tumors [46]. NDRG1 shows 
high expression in oral and oropharyngeal carcinomas; however, it is associated with a low 
metastases rate [47]. PABPC1 can contribute to the aggressiveness of inflammatory breast 
carcinoma [48]. STAU1 stabilizes the mRNA in undifferentiated cells but can mediate its 
degradation in differentiated cells [49]. TTN stands out in rankings of genes carrying driver 
mutations [50,51]. Finally, YWHAZ shows high expression in patients with esophageal cancer, 
and it is associated with a poor clinical prognosis [52].   
In hepatocellular carcinoma, recent data suggested a model where secreted agrin serves 
as a mechanotransduction signal to activate YAP protein in response to stiff ECM [53]. ECM 
stiffness (resistance to deformation) is one of the potent regulators of cell physiology such as 
proliferation, morphology, and migration [54]. Future research would have to evaluate whether 
these phenomena and molecular functions explain how agrin promotes the progression of oral 
cancer. 
To translate the agrin network into clinical outcomes, we demonstrated that patients 
with HNSCC who show a high gene expression of the agrin network have a lower survival rate. 
To our understanding, there is no previous research showing this potential prognosis panel.  
In conclusion, our results demonstrate that agrin is important for oral cancer-associated 
events and is a strong candidate as a therapeutic target for OSCC. In addition, agrin network 
panel represents a prognostic signature for oral cancer. This study deepens the understanding 
of the pathophysiological role of agrin in oral cancer progression. 
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FIGURE CAPTIONS 
 
 
 
Figure 1. Schematic workflow. The effect of agrin silencing in cancer events was 
evaluated using both in vitro and in vivo (orthotopic model) experiments. We induced the 
overexpression of a secreted agrin fragment, and ligands able to bind to agrin were identified 
using mass spectrometry after protein immunoprecipitation. Once the agrin ligands were 
identified, we visualized the agrin network and evaluated its potential prognosis. 
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Figure 2. Agrin silencing decreased oral cancer progression, in vitro. (A) Agrin 
mRNA quantification in various cell lines (left panel). HMK cells were used as controls. 
Western blotting confirmed the presence of agrin (secretome fraction, right panel). Multiple 
bands may represent proteolytic cleavage products. Ponceau red was used as loading control. 
(B) Verification of agrin silencing by RT-qPCR and dot blot. Actin was used as control. (C) 
Proliferation, migration, invasion (absorbance at 450, 600 and 620 nm, respectively) and 
epithelial-mesenchymal transition (EMT) experiments. (D) Focus formation assay. Darkest 
intensity in millions of pixels. Scale bars, 2 cm. (E) Tumor sphere formation. Scale bars, 100 
µm. Tumorsphere area in µm2 (x100,000 to SCC9 and x10,000 to HSC-3). For all PCR 
experiments, data were normalized with GAPDH gene (relative quantification/GADPH, mRNA 
axis). Data are the means ± SD (Student’s t-test, *P-value ≤0.05, **≤0.001). 
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Figure 3. Agrin regulates the severity of oral cancer. (A) An orthotopic model of 
OSCC was established, inoculating HSC-3 cells into the lateral border of the tongue of NOD-
SCID mice. Animals received control (shControl) or silenced (shAgrin) cells. Representative 
images are shown (day 21). Scale bars, 0.2 cm, 400 µm. (B) Histopathological characteristics 
of oral cancers (*P-value ≤ 0.05 Pearson's Chi-square test). 
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Figure 4. Agrin network represents a community with prognostic potential. (A) C-
terminal agrin-GFP construction used as Ct-agrin in transfection experiments 
(PRO_0000421622). (B) IPAD predicted diseases from Ct-agrin ligands. Cellular model was 
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validated due to the presence of tongue cancers within the top 5 ranking. (C) Representative 
GO terms for the agrin network. (D) Agrin network gene expression is altered when agrin is 
silenced in OSCC cell lines. (E) Oncomine meta-analysis for gene expression. Color intensity 
equals the percentile. The names of OSCC datasets (Estilo to Ye) are written on this basis. The 
agrin network is overexpressed in oral cancer. (E) Immunohistochemical staining of agrin 
network, using the Cancer Atlas. (F) High gene expression of agrin network is associated with 
lower overall survival rates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
68 
 
REFERENCES 
 
1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 
2015; 65: 87-108. 
2. Rivera C, Venegas B. Histological and molecular aspects of oral squamous cell 
carcinoma (Review). Oncol Lett 2014; 8: 7-11. 
3. Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell 
carcinoma--an update. CA Cancer J Clin 2015; 65: 401-421. 
4. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the 
hallmarks of cancer. EMBO Rep 2014; 15: 1243-1253. 
5. Rivera C, Oliveira AK, Costa RAP, et al. Prognostic biomarkers in oral squamous cell 
carcinoma: a systematic review. Oral Oncol 2017; 72: 38-47. 
6. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 
9 Suppl 5: 10-17. 
7. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer 
progression. J Cell Biol 2012; 196: 395-406. 
8. Chakraborty S, Lakshmanan M, Swa HL, et al. An oncogenic role of Agrin in 
regulating focal adhesion integrity in hepatocellular carcinoma. Nat Commun 2015; 6: 
6184. 
9. Bezakova G, Ruegg MA. New insights into the roles of agrin. Nat Rev Mol Cell Biol 
2003; 4: 295-308. 
10. Xiong W-C, Mei L. Agrin to YAP in Cancer and Neuromuscular Junctions. Trends in 
Cancer 2017; 3: 247-248. 
11. Kawahara R, Granato DC, Carnielli CM, et al. Agrin and perlecan mediate 
tumorigenic processes in oral squamous cell carcinoma. PLoS One 2014; 9: e115004. 
69 
 
12. Neill T, Schaefer L, Iozzo RV. Decoding the Matrix: Instructive Roles of 
Proteoglycan Receptors. Biochemistry 2015; 54: 4583-4598. 
13. Drey M, Sieber CC, Bauer JM, et al. C-terminal Agrin Fragment as a potential marker 
for sarcopenia caused by degeneration of the neuromuscular junction. Exp Gerontol 
2013; 48: 76-80. 
14. Scherbakov N, Knops M, Ebner N, et al. Evaluation of C-terminal Agrin Fragment as 
a marker of muscle wasting in patients after acute stroke during early rehabilitation. J 
Cachexia Sarcopenia Muscle 2016; 7: 60-67. 
15. Steubl D, Hettwer S, Vrijbloed W, et al. C-terminal agrin fragment--a new fast 
biomarker for kidney function in renal transplant recipients. Am J Nephrol 2013; 38: 
501-508. 
16. Yu D, Li HX, Liu Y, et al. The Reference Intervals for Serum C-Terminal Agrin 
Fragment in Healthy Individuals and as a Biomarker for Renal Function in Kidney 
Transplant Recipients. J Clin Lab Anal 2017; 31. 
17. Klein-Scory S, Kubler S, Diehl H, et al. Immunoscreening of the extracellular 
proteome of colorectal cancer cells. BMC Cancer 2010; 10: 70. 
18. Hardt M, Lam DK, Dolan JC, et al. Surveying proteolytic processes in human cancer 
microenvironments by microdialysis and activity-based mass spectrometry. 
Proteomics Clin Appl 2011; 5: 636-643. 
19. Wiegand S, Dunne AA, Muller HH, et al. Metaanalysis of the significance of matrix 
metalloproteinases for lymph node disease in patients with head and neck squamous 
cell carcinoma. Cancer 2005; 104: 94-100. 
20. Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of 
animals in cancer research. Br J Cancer 2010; 102: 1555-1577. 
70 
 
21. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New 
York: Garland Science. Available from: 
https://www.ncbi.nlm.nih.gov/books/NBK21054/.  2002. 
22. Stepanenko AA, Dmitrenko VV. HEK293 in cell biology and cancer research: 
phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype 
evolution. Gene 2015; 569: 182-190. 
23. Neuhuber B, Daniels MP. Targeting of recombinant agrin to axonal growth cones. Mol 
Cell Neurosci 2003; 24: 1180-1196. 
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408. 
25. Rivera C. Agarose floor technique: a simple scaffold-free method for 3D cell culture 
and multicellular tumor spheroid formation. Anal Quant Cytopathol Histpathol 2017; 
39: 114-115. 
26. Aragao AZ, Belloni M, Simabuco FM, et al. Novel processed form of syndecan-1 
shed from SCC-9 cells plays a role in cell migration. PLoS One 2012; 7: e43521. 
27. Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass 
spectrometry-based shotgun proteomics. Nat Protoc 2016; 11: 2301-2319. 
28. Tyanova S, Temu T, Sinitcyn P. The Perseus computational platform for 
comprehensive analysis of (prote)omics data. Nat Methods 2016; 13: 731-740. 
29. Winck FV, Prado Ribeiro AC, Ramos Domingues R, et al. Insights into immune 
responses in oral cancer through proteomic analysis of saliva and salivary extracellular 
vesicles. Sci Rep 2015; 5: 16305. 
30. Zhang F, Drabier R. IPAD: the Integrated Pathway Analysis Database for Systematic 
Enrichment Analysis. BMC Bioinformatics 2012; 13 Suppl 15: S7. 
71 
 
31. Muetze T, Goenawan IH, Wiencko HL, et al. Contextual Hub Analysis Tool (CHAT): 
A Cytoscape app for identifying contextually relevant hubs in biological networks. 
F1000Research 2016; 5: 1745  
32. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open 
platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 
2: 401-404. 
33. TCGA. The Cancer Genome Atlas Network. Comprehensive genomic characterization 
of head and neck squamous cell carcinomas. Nature 2015; 517: 576-582. 
34. Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein 
interaction networks, integrated over the tree of life. Nucleic Acids Res 2015; 43: 
D447-452. 
35. Binns D, Dimmer E, Huntley R, et al. QuickGO: a web-based tool for Gene Ontology 
searching. Bioinformatics 2009; 25: 3045-3046. 
36. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, 
pathways, and networks in a collection of 18,000 cancer gene expression profiles. 
Neoplasia 2007; 9: 166-180. 
37. Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the 
human proteome. Science 2015; 347: 1260419. 
38. Goswami CP, Nakshatri H. PROGgeneV2: enhancements on the existing database. 
BMC Cancer 2014; 14: 970. 
39. Wichmann G, Rosolowski M, Krohn K, et al. The role of HPV RNA transcription, 
immune response-related gene expression and disruptive TP53 mutations in diagnostic 
and prognostic profiling of head and neck cancer. Int J Cancer 2015; 137: 2846-2857. 
40. Farnedi A, Rossi S, Bertani N, et al. Proteoglycan-based diversification of disease 
outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as 
unique relapse and overall survival predicting factors. BMC Cancer 2015; 15: 352. 
72 
 
41. Soares MA, Teixeira FC, Fontes M, et al. Heparan Sulfate Proteoglycans May 
Promote or Inhibit Cancer Progression by Interacting with Integrins and Affecting Cell 
Migration. Biomed Res Int 2015; 2015: 453801. 
42. Gao CF, Xie Q, Su YL, et al. Proliferation and invasion: plasticity in tumor cells. Proc 
Natl Acad Sci U S A 2005; 102: 10528-10533. 
43. Tai SK, Li WY, Chu PY, et al. Risks and clinical implications of perineural invasion 
in T1-2 oral tongue squamous cell carcinoma. Head Neck 2012; 34: 994-1001. 
44. Watson IR, Irwin MS, Ohh M. NEDD8 pathways in cancer, Sine Quibus Non. Cancer 
Cell 2011; 19: 168-176. 
45. D'Arcy P, Wang X, Linder S. Deubiquitinase inhibition as a cancer therapeutic 
strategy. Pharmacol Ther 2015; 147: 32-54. 
46. Modelska A, Turro E, Russell R, et al. The malignant phenotype in breast cancer is 
driven by eIF4A1-mediated changes in the translational landscape. Cell Death Dis 
2015; 6: e1603. 
47. Dos Santos M, da Cunha Mercante AM, Nunes FD, et al. Prognostic significance of 
NDRG1 expression in oral and oropharyngeal squamous cell carcinoma. Mol Biol Rep 
2012; 39: 10157-10165. 
48. Bekhouche I, Finetti P, Adelaide J, et al. High-resolution comparative genomic 
hybridization of inflammatory breast cancer and identification of candidate genes. 
PLoS One 2011; 6: e16950. 
49. Kretz M. TINCR, staufen1, and cellular differentiation. RNA Biol 2013; 10: 1597-
1601. 
50. Tan H, Bao J, Zhou X. Genome-wide mutational spectra analysis reveals significant 
cancer-specific heterogeneity. Sci Rep 2015; 5: 12566. 
73 
 
51. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human 
cancer genomes. Nature 2007; 446: 153-158. 
52. Watanabe N, Komatsu S, Ichikawa D, et al. Overexpression of YWHAZ as an 
independent prognostic factor in adenocarcinoma of the esophago-gastric junction. Am 
J Cancer Res 2016; 6: 2729-2736. 
53. Chakraborty S, Njah K, Pobbati AV, et al. Agrin as a Mechanotransduction Signal 
Regulating YAP through the Hippo Pathway. Cell Rep 2017; 18: 2464-2479. 
54. Gweon B, Li Z, Shin Y, et al. Extracellular matrix (ECM)-stiffness regulated cancer 
cell (A549) migration. The FASEB Journal 2016; 30: 923.923-923.923. 
 
74 
 
3 DISCUSSION 
 
Patients with OSCC generally have a poor clinical prognosis. There is a need for better 
prognostic tools to predict the patients’ clinical course, which is important when planning the 
treatment (Almangush et al., 2017). 
Over the years, several molecules with this potential have been proposed, which may 
add an additional value to the classic TNM, clinical stage or degree of differentiation. The aim 
of the first manuscript (published in Oral Oncology) was to identify articles that presented 
prognostic biomarkers for oral cancer, using a systematic review of the literature. We referred 
to them as “potential biomarkers,” due to the absence of a sample size calculation and lack of 
internal/external validations. 
Most of selected articles assessed proteins through immunohistochemistry in biopsies 
from historical archives of their clinical centers. This may be due formalin/paraffin combination 
is the universal method for tissue preservation (Scicchitano et al., 2009), which provided an 
opportunity for these retrospective studies. 
The systematic review identified mostly unique biomarkers. Of the articles reviewed, 
only 5 used a combination of biomarkers. Today it is widely accepted that combinations of 
biomarkers (biomarker signatures) contain much more information than a single biomarker 
(Borrebaeck, 2017).  The use of biomarker signatures may potentiate the discriminatory power 
of candidates identified by our systematic review. 
In the future, widening our search for biomarkers that represent the passing from 
susceptibility to the establishment of a malignant neoplasm may complete our overview with 
respect to the prognostic biomarkers suggested for oral cancer. 
Being able to demonstrate a potential clinical use is the main challenge that the 
prognostic markers must overcome (Kim et al., 2014). The theoretical base of the systematic 
review showed that the search must continue for new molecules that help us to better understand 
the mechanisms of oral cancer. This last point inspired the experimental studies of this thesis, 
which focused on the progression of oral cancer. 
In recent years, the importance of tumoral stroma in the progression of cancer has been 
ever more evident (Sund and Kalluri, 2009). The extracellular matrix (ECM) is a fundamental 
part of tumoral stroma. Since malignant cells are a substantial resource that can be used as 
biomarkers for cancer, the ECM contains factors that may be key to malignant progression. 
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The ECM is composed of highly variable and dynamic components that regulate cell 
behavior (Oskarsson, 2013). The objective of the second manuscript was to evaluate the role of 
an ECM protein, agrin, in the progression of OSCC. 
The silencing of agrin negatively affected the maintenance of key oncogenic phenomena 
for tumoral progression, which may have therapeutic implications that can be explored in the 
future. This confirms that the proteoglycans are important in the progression of oral neoplasms, 
particularly agrin. 
The valuable information obtained through mass spectrometry-based proteomics made 
it possible to identify a group of proteins associated with agrin (agrin binding partners). The 
patients who presented a super high expression of the network displayed unfavorable survival 
curves. 
Proteomics analysis is a promising approach for the discovery of biomarkers and 
therapeutic targets (Moghieb et al., 2013). Mass spectrometry-based proteomics is valuable in 
both preclinical and clinical research as it can detect multiple proteins in a biological system 
and correlate these patterns with health status (Maeda et al., 2015). It is the most important tool 
in the identification and characterization of proteins in proteomics due to the general feasibility 
and sensitivity of the analysis (Moghieb et al., 2013). 
The pending challenge for our second study is to explore immunohistochemistry 
staining patterns of agrin in benign, premalignant and malignant lesions and examine the 
molecular functions that agrin and its binding partners represent, as well as to identify if any of 
these proteins can be more relevantly associated with the prognosis of patients with oral cancer. 
The two studies contained in this doctoral thesis represent, firstly, our search for 
candidates that are associated with the clinical progression of the disease and secondly, our 
effort to continue opening windows, deepening the understanding of molecular mechanisms in 
the malignant neoplasm that is most relevant for dental surgeons, the OSCC. 
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4 CONCLUSION 
 
The systematic review of the literature was useful in identifying prognostic biomarkers 
for oral cancer. The identified biomarkers were potential due to the lack of validation stages. 
 
Agrin is important in the maintenance of oncogenic events associated with oral cancer, 
which may represent a therapeutic opportunity. Its network is a source of prognostic marker 
signatures for OSCC.  
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